Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cotrifazid--an agent against malaria

E Freerksen1, E W Kanthunkumva, A R Kholowa

  • 1St. Gabriel's Hospital, Namitete, Malawi.

Chemotherapy
|November 1, 1996
PubMed
Summary

A new malaria treatment, Cotrifazid (rifampicin+isoniazid+sulfamethoxazole+trimethoprim), shows very good results and tolerance in 61 patients. This fixed combination therapy offers a promising approach for managing malaria.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Malta Project--a country freed itself of leprosy. A 27-year progress study (1972-1999) of the first successful eradication of leprosy.

Chemotherapy·2001
Same author

Malaria therapy and prophylaxis with cotrifazid, a multiple complex combination consisting of rifampicin + isoniazid + sulfamethoxazole + trimethoprim.

Chemotherapy·1995
Same author

Critical comments on the treatment of leprosy and other mycobacterial infections with clofazimine.

Arzneimittel-Forschung·1992
Same author

[Short-term chemotherapy of leprosy using the combination rifampicin + cotrimoxazole + isoniazid].

Medizinische Klinik (Munich, Germany : 1983)·1991
Same author

A new short-term combination therapy of leprosy.

Chemotherapy·1991
Same author

[Chemotherapy of opportunistic infections in AIDS].

Fortschritte der Medizin·1990

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Tropical Medicine

Background:

  • Malaria remains a significant global health challenge, necessitating novel therapeutic strategies.
  • Antimalarial drug resistance is a growing concern, driving the need for combination therapies.
  • Fixed-dose combinations offer potential advantages in adherence and efficacy.

Purpose of the Study:

  • To evaluate the efficacy and tolerance of a new fixed multiple combination therapy, Cotrifazid, for malaria treatment.
  • To discuss fundamental considerations regarding combination antimalarial therapy, including chemoresistance and synergistic effects.

Main Methods:

  • Clinical evaluation of 61 patients with various forms of malaria treated with Cotrifazid.
  • Assessment of treatment outcomes and patient tolerance.
  • Discussion of theoretical principles related to combination drug therapy.

Main Results:

  • Very good treatment results were reported for the 61 patients evaluated.
  • The tolerance of the Cotrifazid treatment was found to be good.
  • The study supports the use of fixed multiple drug combinations in malaria management.

Conclusions:

  • Cotrifazid, a fixed combination of rifampicin, isoniazid, sulfamethoxazole, and trimethoprim, demonstrates significant efficacy and good tolerance in malaria treatment.
  • The findings support the transition from monotherapy to combination therapy to combat chemoresistance.
  • The principle of "multidisease therapy" is considered in the context of combination drug approaches.

Related Experiment Videos